• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1% SODIUM HYALURONATE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1% SODIUM HYALURONATE Back to Search Results
Catalog Number 6301182010
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Death (1802)
Event Date 09/24/2018
Event Type  Death  
Event Description
Deceased [death].Case (b)(4) is a serious spontaneous case received from a non health professional via a regulatory authority in united states.This report concerns a patient of unknown age and gender who was deceased after treatment with intra-articular euflexxa (sodium hyaluronate) solution for injection, with unknown concentration 20 mg, weekly for 3 weeks, for osteoarthritis from 2014 to 2018.It was reported that patient was deceased.No additional information was reported.The patient died on (b)(6) 2018 due to an unknown cause.Action taken with euflexxa was not applicable.At the time of this report, the outcome of deceased was fatal.Medical history was not reported.The following concomitant medications were reported: alprazolam, ambien, folic acid, inspra, losartan potassium, multi vitamin with fluoride, nitrolingual, "nortriptylin", norvasc, oxycodone, protonix, robaxin and vitamin c.All events in the case were reported as serious.At the time of reporting the case outcome was fatal.Overall listedness (core label) is unlisted.Reporter causality: related.Company causality: unassessable.Other case numbers: case number, others = mw5080621.This ae occurred in "teh" us and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in eu because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer.No corrective action was done by the manufacturer or requested by regulators.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EUFLEXXA
Type of Device
1% SODIUM HYALURONATE
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
be'er tuvia industrial zone
pob 571
kiryat malachi, 83104
IS  83104
Manufacturer (Section G)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
be'er tuvia industrial zone
pob 571
kiryat malachi, 83104
IS   83104
Manufacturer Contact
100 interpace parkway
parsippany, NJ 07054
9737961600
MDR Report Key8061003
MDR Text Key126912672
Report Number3000164186-2018-00037
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P010029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type other
Reporter Occupation Other
Type of Report Initial
Report Date 11/12/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/12/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Device Expiration Date08/27/2019
Device Catalogue Number6301182010
Device Lot NumberN16434A
Was Device Available for Evaluation? No
Date Manufacturer Received10/29/2018
Is the Device Single Use? Yes
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Death;
-
-